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Abstract
Background and aims: High concentrations ofmethylated thiopurinemetabolites, such as 6-methyl
mercaptopurine, are associated with hepatotoxicity during administration of the conventional
thiopurines azathioprine or 6-mercaptopurine in IBD patients. Metabolization of the non-
conventional thiopurine 6-thioguanine does not generate 6-methyl mercaptopurine. Hence, the
aim of our study was to evaluate hepatotoxicity during 6-thioguanine in IBD patients who previously
failed conventional thiopurines due to 6-methyl mercaptopurine associated hepatotoxicity.
Methods: A retrospective single center intercept cohort study was performed of IBD patients using
6-thioguanine between January 2006 and July 2010 after failing conventional thiopurine therapy
due to 6-methyl mercaptopurine associated hepatotoxicity. The primary outcome was the
occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology
Criteria for Adverse Events.rcaptopurine; AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; 6-TGN, 6-thioguanine
l transferase; HBI, Harvey–Bradshaw Index; MTLWI, Modified Truelove and Witts Index.
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96 D.P. van Asseldonk et al.Results: Nineteen patients were included. Median duration of 6-thioguanine therapy (median daily
dosage 21 mg (9–24)) was 23 weeks (6–96). Hepatotoxicity did not reoccur in 15 out of 19, whereas
grade 1 toxicity persisted in 4 patients (pb0.001). Median aspartate aminotransferase and alanine
aminotransferase concentrations decreased from 34 U/l (20–59) and 64 U/l (15–175) to 23 U/l
(18–40; p=0.003) and 20 U/l (14–48; p=0.019), respectively.
Conclusion: Hepatotoxicity does not reoccur during 6-thioguanine treatment inmost IBDpatientswho
failed conventional thiopurines due to 6-methyl mercaptopurine associated hepatotoxicity. Hence, at
least at short-term, 6-thioguanine appears a justifiable alternative thiopurine for these IBD patients.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.hiopurinemetabolism in a pre
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Drug therapy for inflammatory bowel disease (IBD) roughly
consists of a remission induction phase and remission mainte-
nance phase. The conventional thiopurines azathioprine (AZA)
and 6-mercaptopurine (6-MP) have been used as maintenance
treatmentwith reasonable success. However, on the long-term
there is a fairly largeproportion of IBDpatients, up to30 to 50%,
which fails these therapies, mainly due to adverse events
and therapy refractoriness.1 A substantial part of treatment
failures is believed to result from a deviant thiopurine
metabolism. To become efficacious AZA and 6-MP need to be
metabolized into the pharmacologically active 6-thioguanine
nucleotides (6-TGN). However, catabolic conversions may
hamper this bioactivation (Fig. 1). Thiopurine S-methyl
transferase (TPMT), the activity of which follows a trimodal
distribution in the Caucasian population, drives the methyla-
tion of AZA and 6-MP into 6-methyl mercaptopurine and 6-
methyl mercaptopurine ribonucleotides, together abbreviated
as 6-MMP.2 High concentrations of 6-MMP are associated with
overall treatment failure and hepatotoxicity in particular.1,3
Despite dose escalation a proportion of patients fails to achieve
therapeutic concentrations of 6-TGN (N235 pmol/8×10*8 red
blood cells (RBC)), mostly in favor of 6-MMP production. These
patients are called preferential 6-MMP metabolizers.4,5 For
this specific sub-group of patients alternative maintenancefer
ctio
ac
PM
photreatments have been suggested, including low dosed AZA or
6-MP in combination with allopurinol, methotrexate (presum-
ably only in case of Crohn's disease) or anti-TNFα antibody
therapies.6,7 In addition, 6-thioguanine (6-TG) has been
advocated as an escape/rescue maintenance treatment in
patients who previously failed conventional thiopurine
therapy.8,9 Since 6-TG only needs one enzymatic conversion
into 6-TGN and its metabolization does not result in 6-MMP
production, we hypothesized 6-TG to be a convenient
alternative thiopurine, in particular for preferential 6-MMP
metabolizers. Hence, the main objective of this study was to
explore 6-TG toxicity in preferential 6-MMP metabolizers with
hepatotoxicity.
2. Materials and methods
2.1. Patient population
In accordance with the 2008 Declaration of Helsinki a
retrospective single center intercept cohort study of IBD
patients using 6-TG between January 2006 and July 2010 was
performed. Diagnoses of Crohn's disease (CD) and ulcerative
colitis (UC)wereestablished by standard clinical, endoscopical
and/or histological criteria.10 All patients required immuno-
suppressive therapy (chronic active disease or glucocorticoid
dependent) and previously failed AZA or 6-MP therapy due toential 6-methyl mercaptopurine (6-MMP)metabolizer results in the
n of pharmacologically active 6-thioguanine nucleotides (6-TGN).
id; 6-TIMP, 6-thioinosine monophosphate; 6-TITP,6-thioinosine
T, thiopurine S-methyl transferase; HGPRT, hypoxanthine-guanine
sphate pyrophosphohydrolase.
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international guideline/recommendation.11 Resistance to AZA
or MP was defined as persisting or deteriorating active disease
at 6 months of therapy despite dose escalation, if appropriate
and feasible. 6-Thioguanine, prescribed in a daily dose of
approximately 0.3 mg/kg,was administered as 18, 21 or 24 mg
capsules (generic). Informed consent was obtained from all
patients prior to initiation of 6-TG. Contraindications for
receiving 6-TG were: active infection, (expected) pregnancy,
lactation and pre-existing known liver disease.
Patients who had a preferential 6-MMP metabolism and
developed hepatotoxicity during AZA or 6-MP therapy were
identified and retrieved from a prospectively maintained
cohort database. A preferential 6-MMP metabolism was
arbitrarily defined as a 6-MMP/6-TGN ratio above 20 in
combination with 6-MMP concentrations above 5700 pmol/
8×10*8 RBC. Hepatotoxicity was defined as at least one of the
following parameters over the upper limit of its normal
range: aspartate aminotransferase N45 U/l, alanine
aminotransferaseN45 U/l, alkaline phosphataseN125 U/l,
gamma glutamyl transferaseN45 U/l and bilirubinN17 μmol/
l. Patients with pre-existing liver test abnormalities, prior to
initiation of the conventional thiopurines, were excluded from
the analysis. Moreover, patients with taking serological blood
tests suggestive of viral or auto-immune hepatitis as well as
primary liver disease or liver injury possibly related to other
medications were excluded from analysis.
Data concerning patient demographics, clinical charac-
teristics, laboratory results, and co-treatment with 5-
aminosalicylates, corticosteroids, and other immunomodulating
drugs were collected from patient record files. An evaluation
point was designated as a clinic visit, usually occurring every
3 months, corresponding to each thiopurine metabolite mea-
surement that was obtained along with routine blood tests:
one prior to switching to 6-TG after at least 6 weeks of AZA or
6-MP and the other after at least 6 weeks of 6-TG treatment.2.2. Outcome measures
The primary outcome was the frequency and severity of
hepatotoxicity during 6-TG treatment compared with during
conventional thiopurine therapies. Secondary outcomes
included other adverse events, thiopurine metabolite mea-
surement, disease activity and corticosteroid use. The
severity of hepatotoxicity and the other adverse events
was scaled according to the Common Terminology Criteria
for Adverse Events (CTCAE, version 4.03) (Table 2).12 All
outcome measures were assessed at both clinical evaluation
points. Corticosteroid use was defined as the use of an
equivalent of prednisolone 10 mg/day or budesonide 3 mg/
day during both thiopurine regimens. Thiopurine metabolite
concentrations were determined in RBC from heparinized
blood (6 mL) by reversed-phase high-performance liquid
chromatography according to a modified method of Dervieux
and Boulieu as previously reported.13,14 The obtained 6-TGN
values were subsequently adjusted to values that would have
been obtained by using the method of Lennard et al.15,16
Disease activity was assessed by calculating the Harvey–
Bradshaw Index (HBI) for CD and the Modified Truelove and
Witts Index (MTLWI) for UC, if data were available.17,18
Clinical response was defined by a HBI score reduction frombaseline of ≥50% or a score b5 for CD and a MTLWI score
reduction from baseline of ≥50% or a score of b3 for UC.
2.3. Statistical methods
Quantitative variables were described as means with their
standard deviations or as medians with their range if not
normally distributed. Depending on the distribution, paramet-
ric and non-parametric tests including T-test, Wilcoxon signed
rank test and Sign exact test, were used to test for differences
within and between groups. P values less than 0.05 were
considered statistically significant. SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
3. Results
3.1. Patient characteristics
Nineteen patients including five males were retrieved from
the prospectively maintained IBD database and eligible for
analysis. Their mean age was 44 years (SD 11). Out of the 19
included patients, 12 were diagnosed with ulcerative colitis
and 7 had Crohn's disease. Patient and disease characteris-
tics are tabulated in Table 1. Thiopurine pre-treatment
included AZA (n=5), 6-MP (n=9), or both (n=5). Median
duration of pre-treatment was 9 months, ranging from 0 to
104 months. Pre-treatment metabolite concentrations were
fitting the criteria of a preferential 6-MMP metabolism with a
median 6-MMP/6-TGN ratio of 126 (42–323), a median 6-MMP
concentration of 18,150 pmol/8×108 RBC (6280–33,570) and
a median 6-TGN concentration of 127 pmol/8×108 RBC (35–
280). All patients developed hepatotoxicity during thiopur-
ine pre-treatment; 4 patients showed grade 2, whereas 15
showed grade 1 toxicity. Other observed adverse events
during preceding thiopurine treatment included myelotoxi-
city (n=3), nausea (n=2) and arthralgia (n=1).
3.2. 6-Thioguanine therapy
With a median duration of 23 weeks (range 6–96), 6-TG was
prescribed in a mean dose of 21 mg per day (SD 4 mg),
corresponding to 0.30 mg/kg (SD 0.05). Three out of 19
patients (16%) developed adverse events during 6-TG therapy,
none ofwhich resulted in drugwithdrawal or dose adjustment.
Two out of these three had developed myelotoxicity in
combination with hepatotoxicity during preceding thiopurine
treatment, one of whom experienced arthralgia grade 1 and
the other a Clostridium difficile enterocolitis grade 2 during 6-
TG therapy. The third patient developed myalgia grade 1.
During follow-up the median 6-TGN concentration was
427 pmol/8×108 RBC ranging from 126 to 800 pmol/8×108
RBC. As expected no 6-MMP was detected. Additional
laboratory results are shown in Table 3.
3.3. 6-Thioguanine induced hepatotoxicity
During 6-TG treatment the frequency of hepatotoxicity,
indicated by the CTCAE scores, decreased as compared
during preceding thiopurine treatment (pb0.001). In Fig. 2 it
is depicted that median AST and ALT concentrations
Table 1 Patient characteristics (n=19).
Gender (M:F) 5:14
Age at diagnosis IBD, year (S.D.) 32.2 (11.9)
Body mass index (S.D.) 24.1 (3.7)
Disease classification and localization
CD 7
Below 17 year (A1) –
17–40 year (A2) 3
Above 40 year (A3) 4
Ileal (L1) 2
Colonic (L2) 1
Ileocolonic (L3) 4
Isolated upper disease (L4) –
Non-stricturing, non-penetrating (B1) 1
Stricturing (B2) 5
Penetrating (B3) 1
Perianal disease modifier (p) 2
UC 12
Proctitis (E1) 2
Left-sided (E2) 8
Pancolitis (E3) 2
Duration disease to start 6-TG, year (range) 8.8 (0.5–32.9)
Pre-treatment (AZA:6-MP:both) 5:9:5
AZA dose in mg/day (S.D.) 145 (37)
AZA dose in mg/kg/day (S.D.) 2.26 (0.48)
6-MP dose in mg/day (S.D.) 96 (22)
6-MP dose in mg/kg/day (S.D.) 1.4 (0.29)
Duration pre-treatment, months (range) 9 (1–104)
Metabolite concentrations with AZA/6-MP
6-MMP, pmol/8×108 RBC (range) 18,150 (6280–33,570)
6-TGN, pmol/8×108 RBC (range) 127 (35–280)
6-MMP/6-TGN ratio (range) 126 (42–323)
Age at initiation 6-TG, year (S.D.) 44.3 (11.2)
Days between pre-treatment and 6-TG (range) 9 (0–494)
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(18–40; p=0.003) and 20 U/l (14–48; p=0.019). Hepatotox-
icity completely resolved In 15 patients (79%): 4 from grade 2
toxicity to grade 0, and 11 from grade 1 to 0 (Fig. 3). In
another 4 patients hepatotoxicity remained grade 1, albeitTable 2 Common Terminology Criteria for Adverse Events (CTCA
Grade
Adverse event 1 2
AST increased NULN−3.0×ULN N3.0−5.0×ULN
ALT increased NULN−3.0×ULN N3.0−5.0×ULN
AP increased NULN−2.5×ULN N2.5−5.0×ULN
Gamma-GT increased NULN−2.5×ULN N2.5−5.0×ULN
Bilirubine increased NULN−1.5×ULN N1.5−3.0×ULN
Arthralgia Mild pain Moderate pain
Myalgia Mild pain Moderate pain
Enterocolitis – N3 unformed stools p
24 h or duration of il
N48 h; moderate
abdominal pain
The upper limits of normal (ULN): AST, aspartate aminotransferase 45
AP, alkaline phosphatase 125 U/l; Gamma-GT, gamma glutamyl transfvery subtle with ALT concentrations of 46, 47 and 48 U/l in
three and a bilirubine concentration of 22 μmol/l in one. Two
out of these four patients also experienced other adverse
events during 6-TG (one arthralgia and the other myalgia).
Total 6-TG dosage, 6-TG dosage per kg, 6-TGN concentrationE v4.0)(12).
3 4
N5.0−20.0×ULN N20.0×ULN
N5.0−20.0×ULN N20.0×ULN
N5.0−20.0×ULN N20.0×ULN
N5.0−20.0×ULN N20.0×ULN
N3.0−10.0×ULN N10.0×ULN
Severe pain –
Severe pain –
er
lness
Antibiotic, endoscopic
or operative intervention
indicated; profuse watery
diarrhea; bloody stools; fever
Life-threatening
consequences;
urgent intervention
indicated
U/l; ALT, alanine aminotransferase 45 U/l;
erase 45 U/l; bilirubine 17 μmol/l.
Table 3 Laboratory results.
Parameter AZA/6-MP 6-TG P
AST (U/l) 34 (20–59) 23 (18–40) 0.003
ALT (U/l) 64 (15–175) 20 (14–48) 0.019
AP (U/l) 67 (35–114) 74 (32–112) 0.649
Gamma-GT (U/l) 28 (9–116) 21 (6–45) 0.040
Bilirubine (mmol/l) 13 (5–31) 8 (6–22) 0.030
Hemoblobine (mmol/l) 7.7 (4.3–9.0) 8.2 (5.9–9.2) 0.143
Leukocyte count
(×10*9/l)
6.4 (1.0–9.8) 6.5 (3.9–15.3) 0.210
Platelet count
(×10*9/l)
297 (35–518) 331 (129–422) 0.935
C reactive protein
(mg/l)
2 (2–255) 3 (2–83) 0.84
AZA/6-MP = azathioprine and or 6-mercaptopurine pre-treatment;
median duration 9 months (1–104).
6-TG = 6-thioguanine therapy; median duration 23 weeks (6–96).
Figure 3 Severity of hepatotoxicity. Severity of hepatotoxic-
ity during preceding thiopurine treatment (open dots) and 6-TG
therapy (filled dots), assessed by the Common Terminology
Criteria for Adverse Events; p=b0.001. In 4 patients the
hepatotoxicity grade was equal between both treatments.
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compared to the other 11 (data not shown). All patients
continued 6-TG therapy as these adverse events were all
considered of minor clinical importance in comparison to the
beneficial therapeutical effects of 6-TG treatment. In two
patients who had been using 6-TG for at least 1 year a routine
liver biopsy was performed that in both cases revealed noFigure 2 Changes in transaminase concentrations. (a) AST
decreases from a median of 34 U/l (20–59) during preceding
thiopurine treatment to 23 U/l (18–40) during 6-TG therapy;
p=0.003. (b) ALT decreases from a median of 64 U/l (15–175) to
20 U/l (14–48); p=0.019.histological abnormalities. None of these two patients were
among the four patients with persisting or recurrence of
hepatotoxicity.
3.4. Disease activity
From 10 out of the 12 UC patients we were able to assess the
MTLWI both during pre-treatment and during 6-TG treat-
ment. Five out of 10 showed a clinical response during 6-TG
therapy. In 4 out of the 5 patients not showing a clinical
response, MTLWI did not change between both treatments
and remained equal or above 3 points. Deterioration of
disease activity during 6-TG therapy occurred in one patient.
From 5 out of 7 CD patients we were able to assess HBI during
both types of thiopurine treatment. In all 5 patients disease
activity did not change and remained below 5, thus showing a
persistent/on-going clinical response.
3.5. Concomitant treatment
During preceding thiopurine treatment seven patients (six
UC and one CD) received 5-aminosalicylates, while eight
(seven UC and one CD) received these drugs during 6-TG
therapy. Six patients needed corticosteroids during pre-
treatment; these drugs could be completely tapered in three
patients during 6-TG therapy. Three patients remained
corticosteroid dependent but dosages could be reduced,
while another four needed a corticosteroid course during 6-
TG therapy. One patient received adalimumab in addition to
6-TG.
4. Discussion
This study describes a series of IBD patients in most of whom
thiopurine associated hepatotoxicity did not reoccur during
short-term 6-TG administration. Liver test abnormalities
100 D.P. van Asseldonk et al.were statistically significantly ameliorated during 6-TG
administration. Moreover, of the 19 patients with 6-MMP
associated hepatotoxicity, 15 did not show any signs of
hepatotoxicity with 6-TG. In the remaining four patients liver
test abnormalities were subtle and seemed not to deterio-
rate with 6-TG. Only three patients developed some other
minor adverse events that did not result in 6-TG withdrawal,
suggesting 6-TG to be well-tolerated in this difficult to treat
group of patients. These results are similar to the tolerability
reported in previous literature.9,19 In addition, 6-TG seemed
to be effective for remission maintenance in most patients,
although few patients needed on-going corticosteroid
therapy.
During conventional thiopurine therapy hepatotoxicity
may occur in up to 10% and is a major determinant for
therapeutic failure.20 Thiopurine associated hepatotoxicity
may be either an idiosyncratic reaction or a dose-dependent
phenomenon, and has been associated with high concentra-
tions of 6-MMP (N5700 pmol/8×108 RBC).4 Our study further
corroborates this association since 6-TG metabolism does not
bear 6-MMP and hepatotoxicity generally does not reoccur
with 6-TG. The pathogenesis of thiopurine associated
hepatotoxicity is not known, although animal models have
shown deprivation of intracellular reduced glutathion con-
centrations that predisposes to oxidative stress, and anti-
oxidative treatment strategies might be beneficial.21 It
remains indistinct why four patients developed hepatotox-
icity during 6-TG therapy. Since two of these four patients
were part of the three patients who also experienced other
adverse events during 6-TG therapy, a common cause might
be suspected. These patients may exhibit an aberrant 6-TG
metabolism, such as altered TPMT or hypoxanthine guanine
phosphoribosyl transferase (HGPRT) activities. However, this
could not be endorsed by 6-TGN concentrations. As absolute
concentrations of the liver test abnormalities were only just
above the upper limit of their normal range, their clinical
significance might be overestimated. Although unlikely, the
presence of liver disease secondary to IBD such as primary
sclerosing cholangitis could not be excluded in this study.
Safety concerns about the use of 6-TG have emerged over
the past years. This seems to be a dose-dependent effect
rather than solely a drug specific effect.22 While liver
biopsies in patients treated with a high dose of 6-TG often
reveals pathohistological abnormalities including nodular
regenerative hyperplasia, this is not the case with the use of
lower dosages.23–25 Although we believe that 6-TG has a
relatively favorable benefit–risk ratio if dosed around
0.3 mg/kg daily, we still recommend to assess serum liver
tests, blood cell counts and perform liver biopsies on a
regular basis in line with international recommendations as
part of drug safety monitoring.11 The duration of follow-up
of our study was relatively short, therefore only two patients
had underwent a liver biopsy so far. A preferential 6-MMP
metabolism upon conventional thiopurine therapy is not only
related with hepatotoxicity, but also with other adverse
event and drug resistance.26 6-Thioguanine might be indicat-
ed in all patients with thiopurine treatment failure associated
with a preferential 6-MMP metabolism, since dose escalation
of conventional thiopurines will probably result in higher
concentrations of 6-MMP, while 6-TGN concentrations remain
relatively low. Interestingly, in our study the range of pre-
treatment durationwas strikingly large. This implies that theremay be interindividual differences in thiopurine metabolism,
which might change over time into a skewed metabolism, and
differences in susceptibility to hepatotoxicity.
As a proportion of patients in this study was corticosteroid
dependent during 6-TG therapy, it is of interest to evaluate
whether dose escalation would increase 6-TG efficacy or
whether these specific patients represent a group of primary
thiopurine non-responders, including non-response to 6-TG.
Alternatively, the administration of the xanthine oxidase
inhibitor allopurinol in addition to a low dose of AZA or 6-MP
might be a successful option, in particular in preferential 6-
MMP metabolizers but presumably also in other cases of
thiopurine treatment failure.27,28 However, safety concerns
regarding the occurrence of harmful myelotoxicity exist,
while any liver biopsy data to show safety with regard to
NRH-induction are lacking. In addition, there is relatively
little clinical experience with this combination treatment in
contrast to 6-TG therapy.
Although being a cohort study, our study does suffer from
limitations most of which coincide with its retrospective
design. Clinical evaluation points and washout periods were
not standardized that makes comparability more difficult. In
addition, this study was not designed nor powered to study or
establish 6-TG efficacy. Although the number of participants
is relatively small, as a proof of principle this study further
substantiates the association between a skewed thiopurine
metabolism and the occurrence of hepatotoxicity. There is a
strong need for a prospectively designed controlled clinical
trial in which 6-MP is compared with 6-TG with regard to both
efficacy and safety. As a result of the simplistic metabolism
of 6-TG with less potentially harmful metabolites, 6-TG
might be better tolerated with comparable effectiveness
provided that it is properly dosed. At present, we still
recommend performing careful routine safety assessments
upon its prescription.
5. Conclusion
Conventional thiopurine therapy is frequently withdrawn,
hepatotoxicity often being the reason. A substantial part of
this toxicity is associated with high concentrations of 6-MMP
resulting from a deviant thiopurine metabolism. For these
patients 6-TG might be an attractive alternative thiopurine,
which generally does not induce such liver injury since its
metabolization does not involve the production of 6-MMP.
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